Now Playing
Regulated Industries Making Irreversible AI Bets | Ep. 1
Audio is available on Spreaker — see link below.
Artificial intelligence is reshaping regulated industries faster than governance can keep up — from the FDA's lifecycle model overhaul to California's statewide Claude deal and Haleon's $5B Microsoft commitment. Today's briefing tracks the governance gaps, the irreversible enterprise bets, and the signals that will define AI's trajectory in health, government, and beyond.
Audio is available on Spreaker — see link below.
The FDA is quietly rewriting how medical AI gets regulated, and it's one of the most consequential shifts in health tech governance in years. The agency is moving away from the old model, where a device gets approved once and stays frozen, toward a lifecycle-based framework where algorithms can evolve continuously under what's called a Predetermined Change Control Plan.
From regulation to procurement. Haleon, the consumer health company behind brands like Sensodyne and Advil, just signed a five-year Microsoft deal deploying Copilot agents, Azure infrastructure, and zero-trust security across twenty-five thousand employees.
Two frontier model releases gated by government review in two weeks. That's the pattern worth tracking.
Anthropic also launched Claude Sonnet 5 as its new default model for free and Pro users. The benchmark number that matters is sixty-three point two percent on agentic coding tasks.
California's governor announced a statewide agreement making Claude the first AI tool available to all state agencies, cities, and counties, at a fifty percent discount with free workforce training included. There's also a fifteen million dollar cyber defense program attached.
One more development worth noting. Engram, a stealth startup, emerged this week with ninety-eight million dollars from General Catalyst, Kleiner Perkins, and Sequoia to build what it calls a learned memory layer for enterprise AI.
Pulling this back: the thread running through today is regulated industries making irreversible bets while the governance frameworks around them are still incomplete. The FDA's new oversight model is live but untested under stress.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.